How should facial synkinesis be treated, including botulinum toxin type A dosing, rehabilitation protocol, and alternative options?

Facial synkinesis: treatment algorithm (prioritizing morbidity, mortality, and quality of life)

Bold Recommendation: Use botulinum toxin type A (BoNT‑A) combined with structured facial neuromuscular retraining as first‑line therapy to reduce synkinesis, improve symmetry, and enhance quality of life; inject low, targeted doses to affected muscles every 3–4 months, titrating by objective scales and EMG guidance 1, 2.

1) Confirm population and exclude red flags

• Chronic peripheral facial palsy with synkinesis (e.g., post‑Bell’s, iatrogenic, infectious) and stable deficits >6–9 months.
• Exclusions/pitfalls:
  • Acute Bell’s palsy phase: BoNT‑A not for acute paresis; manage per Bell’s palsy guidance and defer chemodenervation to chronic sequelae stage 3.
  • Botulism (toxin-mediated paralysis) is a different entity; do not use cosmetic BoNT in suspected botulism; treat urgently with BAT antitoxin per CDC if applicable 4.
  • Ocular exposure risk: plan eye‑protective measures if weakening orbicularis oculi can worsen lagophthalmos.

2) Baseline assessment to drive dosing and targets

• Use validated scales to set targets and track outcomes:
  • Sunnybrook Facial Grading System (total and synkinesis subscore).
  • Synkinesis Assessment Questionnaire (SAQ) if available.
• Map synkinetic patterns and hyperkinesis:
  • Common affected-side targets: orbicularis oculi (eye closure with smile), platysma, mentalis, orbicularis oris, levator labii superioris alaeque nasi.
  • Consider contralateral hyperkinesis reduction: frontalis, zygomaticus, depressor labii inferioris, depressor anguli oris for symmetry 2.

3) First-line intervention: BoNT‑A plus neuromuscular retraining (NMR)

• Evidence choice and strength:
  • Systematic review/meta-analysis shows BoNT‑A significantly improves patient-reported synkinesis (SAQ) and function; heterogeneity precludes a single universal map; patient‑tailored, low-dose, multi‑point injections are standard 1.
  • Large retrospective cohort (n=140) with standardized protocol: mean 15.7 IU per session, significant Sunnybrook improvement and synkinesis reduction; emphasizes NMR as essential adjunct 2.
• Dosing and injection protocol (OnabotulinumtoxinA units; adapt equivalence if using other A-type preparations):
  • Start low, distribute across multiple points; typical per‑point dose 0.6–2.5 U; session totals commonly 10–25 U affected side; add 5–20 U contralateral if needed for balance 5, 1, 2.
  • Practical starter template (modify by EMG/response):
    • Affected side:
      • Orbicularis oculi: 1–2 U per point x 2–4 points lateral lower lid/crow’s foot; avoid medial points to limit lagophthalmos.
      • Platysma: 1–2 U per point x 4–6 points along band(s).
      • Mentalis: 1–2 U per point x 2 points.
      • Orbicularis oris: 0.5–1 U per point x 2–4 points (avoid dysarthria/dysphagia).
      • LL SAN (levator labii superioris alaeque nasi): 1 U x 1–2 points for smile‑snarl synkinesis.
    • Contralateral (for symmetry if nonparetic hyperkinesis dominates):
      • Frontalis: 1–2 U per point x 2–4 points.
      • Zygomaticus major/minor: 1–1.5 U per point x 2–3 points.
      • Depressor anguli oris: 1–2 U x 1–2 points.
      • Depressor labii inferioris: 0.5–1 U x 1–2 points (caution for smile/lip incompetence).
  • Guidance:
    • Prefer EMG or ultrasound guidance for precision and to minimize spillover 6.
  • Interval:
    • Reassess at 2–3 weeks; repeat every 12–16 weeks based on scale improvement and functional goals 1, 7.
• Rehabilitation protocol (start within 1–2 weeks post‑injection):
  • NMR with biofeedback and mirror work focusing on selective activation, relaxation of co‑contracting muscles, and slow, graded movement patterns 3–5 times/week.
  • Evidence supports improved and more durable gains vs toxin alone; measurable Sunnybrook gains persist beyond 3–4 months when combined 7, 2, 8.
• Outcomes to expect:
  • Mean SAQ improvement ~11.6 points in meta‑analysis 1.
  • Sunnybrook improvements of ~10–18 points after 2 sessions; reduced synkinesis scores; QOL better with combined therapy 2, 7.

4) Escalation and maintenance

• If inadequate response after two cycles:
  • Increase per‑point dose by 0.5–1 U or add injection points in the culpable muscles; reassess contralateral balancing needs.
  • Intensify NMR frequency and incorporate EMG‑biofeedback.
• Maintenance:
  • Continue 3–4‑monthly cycles; aim to decrease total dose over time as motor control improves.
  • Re‑score Sunnybrook/SAQ each visit to anchor decisions.

5) Alternatives and adjuncts

• Chemodenervation options:
  • Any FDA‑approved BoNT‑A formulation is acceptable; OnaBoNT‑A most studied in facial palsy literature; formulations for dystonia/blepharospasm have comparable class efficacy per AAN summary 9. Use established conversion caution; prioritize safety and per‑point low doses.
• Surgical options (for refractory, function-limiting synkinesis or asymmetry after optimized BoNT‑A+NMR):
  • Selective neurectomy, myectomy, or nerve/muscle transfer; reserve for specialized centers; still maintain BoNT‑A/NMR perioperatively 10.

6) Safety, pitfalls, and how to avoid them

• Common pitfalls:
  • Over‑weakening orbicularis oris → drooling/dysarthria; keep per‑point doses ≤1 U and lateralize injections.
  • Lagophthalmos/dry eye after orbicularis oculi dosing; avoid medial/lower pretarsal points; pre‑plan lubrication/taping.
  • Asymmetry from ignoring contralateral hyperkinesis; use balanced, small‑dose contralateral strategy when indicated 2.
  • Skipping rehabilitation; BoNT‑A alone yields shorter durability and less functional retraining; always pair with NMR 2, 7, 8.
• Adverse effects:
  • Typically mild/transient; serious systemic effects are rare at facial doses 5.
• Documentation:
  • Record muscles, points, units per point, scales (Sunnybrook, SAQ), photos/videos to guide precise titration.

7) Why this approach (evidence rationale, focused on QOL)

• Highest‑quality, most recent syntheses show BoNT‑A improves synkinesis, symmetry, and patient‑reported outcomes with low risk; combining with NMR improves magnitude and durability, directly benefiting daily function and psychosocial QOL 1, 2, 7.
• Bell’s palsy guideline acknowledges BoNT for chronic synkinesis management among rehabilitative options, aligning specialty practice 3.
• AAN guidance supports class efficacy of BoNT‑A across cranial dystonias, supporting safety and neurotoxin class effect in targeted craniofacial muscles 9.

8) Concrete starter order set (OnabotulinumtoxinA)

• Total session dose: 15–30 U.
• Affected side:
  • Orbicularis oculi: 1 U x 3 points lateral.
  • Platysma: 1.5 U x 4 points along band.
  • Mentalis: 1 U x 2 points.
  • LL SAN: 1 U x 1 point.
  • Orbicularis oris: 0.5 U x 2 lateral points.
• Contralateral (if needed for symmetry):
  • Frontalis: 1 U x 2 points.
  • Zygomaticus major: 1 U x 2 points.
  • DAO: 1 U x 1 point.
• Follow-up at 2–3 weeks to adjust; initiate NMR within 7–14 days; repeat every 12–16 weeks with scale‑based titration 2, 1, 7.